Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
about
Alemtuzumab for patients with chronic lymphocytic leukaemiaAlemtuzumab for chronic lymphocytic leukaemiaSézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and TargetsPrimary cutaneous lymphomas: diagnosis and treatmentCutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementNosocomial Co-Transmission of Avian Influenza A(H7N9) and A(H1N1)pdm09 Viruses between 2 Patients with Hematologic Disorders.Alemtuzumab for B-cell chronic lymphocytic leukemia.Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.Natalizumab and HSV meningitis.Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Alemtuzumab in CLL and other lymphoid neoplasms.Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.Infectious complications associated with monoclonal antibodies and related small moleculesReview of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach.Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.Combination antifungal therapy for disseminated fusariosis in immunocompromised patients : a case report and literature review.Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment.Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies.Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and OncolLate-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.Neurological complications of transplantation: part I: hematopoietic cell transplantation.Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group.Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.Core outcomes and definitions for pediatric fever and neutropenia research: a consensus statement from an international panel.Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.Alemtuzumab and natalizumab: the monoclonal antibody story continues.Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.More than a feeling: new approach required for assessing immunosuppression.Epidemiology of invasive fungal disease in lymphoproliferative disorders.Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.Cryptococcosis, lymphoproliferative disorders and modern day chemotherapy regimens.
P2860
Q24203628-49021B73-BB73-434D-B46A-18C950DEC0BEQ24240922-871F71AB-7F01-4B07-85CF-BD7092AD3D68Q26746551-07EFA8D1-3035-4314-A21B-03D56E25AC39Q26772207-2ED5FCD3-7C63-42A0-A50B-8FB453E5FEEBQ27024076-B17A7B99-FD7B-4852-8CD8-F997674CAB7CQ30385714-F04B58E8-E164-4986-8161-7FAD9F828DEAQ33380135-FBB536B6-9F2A-44CE-B074-CC3CF6C694DCQ34008593-33E4FD17-C57D-4981-B3D9-B13FC35EAC3FQ34222228-5C1A5FF5-2C9E-42A0-B0B8-5AD8BEBA878EQ35019017-2E099A87-992B-454E-8EF1-CF445D7E7021Q36470196-012333B4-9C88-43FA-8CCB-1C5CF8A0BD2BQ36659824-E7D4A3FE-3A4F-4D84-A558-EEBB66431614Q36741655-2B9F5112-6069-4564-A508-BBBDB17B7E5AQ37156636-1179C9FF-942E-4B85-8D6B-F311D61BA328Q37444717-C34E1C28-59F6-4E14-BA89-131B2C0EC466Q37474014-9D80E536-5CE7-471D-840B-4A32105AB36BQ37859378-1AA56A49-6525-4193-8D6E-7B751E7D6B49Q37866827-E69A1F4F-857D-4620-9728-F72469E861F1Q37910256-05077AE3-020F-4A2D-A668-2868DFDD4B05Q37944565-815BA890-28BB-4563-9E55-3D57F9270EA1Q37963498-0E42C52E-B7C2-4FBF-9DCA-B50313A70E60Q38081793-90C350EB-1121-4AAE-8602-87EC43FBF470Q38106512-E0E26DBB-129C-420A-96C5-110E4D29846AQ38132157-338CCEDD-07A8-4474-A788-0810EF565702Q38284455-ACE36F13-F29A-4AA2-8588-6EB2539DE09CQ38284466-6344892D-C12F-49CF-AB50-9636699470BBQ38466180-9A2E0EF6-E32C-4BF7-B0FC-617AA6174EB5Q38703120-8ABA90CB-2F5C-42A9-88B7-8268DC9860C6Q39264020-F4262A7F-F8F2-4B1B-A8DC-D7F7FC1E9F6DQ40130220-8CCFD28B-5A8E-49DF-A530-0D4D9EEA8621Q40180396-F2B5C151-B768-49DA-8344-F0C0C9F0A642Q40515140-D4AF7E9F-3E52-40C9-B887-EB6ED569ACF5Q40672799-3A089E73-97FA-4D2E-B739-3577CC0F2AF1Q42225847-52CC9108-4DB3-446B-8E7A-9DC007552A04Q42238876-E7CA16DA-1499-4DC3-A669-A66C65007DB6Q42910837-111576DD-778F-4F54-8B04-0E76F517B813Q43946878-CA4B347C-E20B-4B70-8C02-14FA597AB2F6Q44100215-6918C954-0CC8-44C6-99ED-D29D6B3835F1Q44189939-F8071A4D-5E8D-4EBF-AA73-063BBF918942Q44793720-4662D053-7359-4405-938E-B1E1959B4DAF
P2860
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Spectrum of infection, risk an ...... ers treated with alemtuzumab*.
@ast
Spectrum of infection, risk an ...... ers treated with alemtuzumab*.
@en
type
label
Spectrum of infection, risk an ...... ers treated with alemtuzumab*.
@ast
Spectrum of infection, risk an ...... ers treated with alemtuzumab*.
@en
prefLabel
Spectrum of infection, risk an ...... ers treated with alemtuzumab*.
@ast
Spectrum of infection, risk an ...... ers treated with alemtuzumab*.
@en
P2860
P50
P1476
Spectrum of infection, risk an ...... ers treated with alemtuzumab*.
@en
P2093
H Miles Prince
John F Seymour
P2860
P356
10.1111/J.1365-2141.2005.05789.X
P407
P577
2006-01-01T00:00:00Z